Early diabetes is starting to look like a liver problem, not just an insulin one

Most explanations of type 2 diabetes still begin and end with insulin: cells become less responsive, glucose stays in the bloodstream, and metabolic control gradually slips. But the new study summarized by MedicalXpress suggests the early disease picture is wider than that.

Researchers at the German Diabetes Center report that glucagon, the hormone that raises blood glucose, is already elevated at an early stage, and that this pattern is linked to metabolic dysfunction-associated steatotic liver disease, or MASLD.

That is not a minor adjustment to the standard story. It changes where the system may be failing first. The analysis compared 50 adults with newly diagnosed type 2 diabetes and 50 adults with normal glucose metabolism. According to the reported findings, post-meal glucagon levels were about 75 percent higher in the diabetes group. The paper appears in Diabetes Care, which gives the result weight, but it does not remove the basic limitation: this is still a modest cohort and an observational metabolic snapshot, not proof of cause and effect.

If the signal holds up, the more interesting issue is not only that glucagon is higher, but why it is higher. The researchers suggest the liver may be less sensitive to glucagon, prompting the body to release more of it. That matters because it reframes glucagon from a secondary marker into a possible sign of early disruption between the pancreas and the liver.

Since the work draws on the German Diabetes Study, its value lies in catching those changes close to diagnosis, before years of disease and treatment complexity make the metabolic picture harder to read.

The clinical importance here is not that a new single cause of diabetes has been found. It is that the disease map may need to be drawn with more precision. MASLD is already recognized as a common partner in metabolic disease, but this study ties it more directly to early hormonal dysregulation. That is relevant because drug development is already exploring approaches that target the glucagon system, especially in liver disease and overlapping metabolic syndromes.

The paper does not deliver a therapy, but it does strengthen the rationale for why that therapeutic direction may be worth pursuing.

The most useful takeaway may be what the study does not claim. It does not say insulin no longer matters, and it does not reduce fatty liver disease to a single hormone. What it does say is that an insulin-only model becomes too narrow when early type 2 diabetes is examined closely enough.

If larger cohorts and intervention studies confirm the pattern, early diabetes may need to be understood as a disorder of several hormonal axes, with the liver acting as one of the first places where the failure becomes visible and, eventually, one of the first places to target.